<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00065611</url>
  </required_header>
  <id_info>
    <org_study_id>030226</org_study_id>
    <secondary_id>03-DK-0226</secondary_id>
    <nct_id>NCT00065611</nct_id>
  </id_info>
  <brief_title>Steroid Treatment for Kidney Disease</brief_title>
  <official_title>Pulse Dexamethasone Over 48 Weeks for Podocyte Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Focal segmental glomerulosclerosis (FSGS) and minimal change disease are kidney diseases that
      are associated with increased excretion of protein in the urine. Approximately half of FSGS
      patients will lose kidney function within 8 years of diagnosis and will require dialysis. The
      purpose of this study is to determine whether intermittent oral steroid therapy can cause
      sustained remission of FSGS and MCD.

      Approximately 70 participants, including adults and children older than age 2, will be
      enrolled in this study. They will receive 48 doses of oral dexamethasone over a period of 48
      weeks. One group will take two daily doses every 2 weeks; the other group will take four
      daily doses every 4 weeks. Doctors will monitor participants before, during, and after the
      steroid treatment with extensive exams and testing. At the completion of the study,
      researchers will evaluate the safety and efficacy of the drug treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The major causes of primary nephritic syndrome in adults and children are idiopathic podocyte
      diseases, minimal change (MCD) and focal segmental glomerulosclerosis (FSGS). Our objective
      is to determine whether intermittent oral dexamethasone administered over 48 weeks can induce
      complete remission in these patients. This is an open-label multi-center pilot study designed
      to obtain preliminary evidence of efficacy and to establish safety. This is part of a
      long-term effort to define the most effective mode of administering pulse dexamethasone and
      is expected to lead to a trial comparing daily prednisone to pulse dexamethasone.

      We will enroll up to 70 patients with nephritic-level proteinuria due to biopsy-proven MCD
      (up to 30 patients) or FSGS (up to 40 patients). We will include adults and children greater
      than 2.0 years of age. Children with MCD must have received a minimum of 4 weeks and a
      maximum of 10 weeks of high-dose daily steroids, since many children are responsive to short
      courses of daily steroids; these requirements will define a steroid-resistant population. For
      children with FSGS and adults with MCD or FSGS, there is no minimum duration of prior
      steroids and there is a maximum of 8 weeks of prior high-dose daily steroids; these
      requirements will define a population that has received a short steroid course without
      response. If steroids have been used, inclusion criteria require persistent nephrotic
      syndrome (thus excluding steroid-sensitive nephrotic syndrome, whether steroid-dependent or
      frequently relapsing).

      Patients may enroll at NIH or at collaborating centers. Those patients who enroll at NIH will
      visit the NIH Clinical Center at least 4 times. Patients enrolled at collaborating centers
      have the option to come to the NIH Clinical Center to complete research tests; under these
      circumstances they will be enrolled as NIH research subjects.

      Patients will receive 48 doses of oral dexamethasone over a period of 48 weeks. Patients will
      be randomized to one of two arms: 2 daily doses every 2 weeks or 4 daily doses every 4 weeks.
      The rationale is to test whether increased frequency dosing has greater efficacy with
      acceptable safety. For adult patients, we have a record of safety with pulse dexamethasone
      from the FSGS Dexamethasone study as well as from published studies for other diseases.
      Therefore, for adults each pulse will be 50 mg/m(2) during the first 12 weeks and each pulse
      will be 25 mg/m(2) during the next 36 weeks. The trial for pediatric patients involves dose
      escalation, as there is little experience with pulse dexamethasone for podocyte diseases in
      this age group. In pediatric stage 1, each dexamethasone pulse will be 25 mg/m(2) over 48
      weeks. When 4 patients in each arm have completed 48 weeks of therapy, safety and efficacy
      will be evaluated. If the evaluation is positive, we will embark on pediatric stage 2, in
      which dexamethasone pulses will be 50 mg/m(2) during the first 12 weeks and 25 mg/m(2) during
      the next 36 weeks (the same as the adult regimen).

      The primary endpoint will be the presence of complete remission 48 weeks after beginning
      therapy. Secondary endpoints will include complete and partial remission at 48 weeks, and
      complete and partial remission at 104 weeks. Assessment of remission will be by 24 hour urine
      collection in adults and children greater than 13.0 years and first void urine samples in
      children less than 13.0 years. Patients will be evaluated for manifestations of steroid
      toxicity, including growth rate (children), ophthalmologic complications, adrenal
      suppression, osteoporosis, a vascular necrosis, and psychological disturbances.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission Status of Patients After Intermittent Oral Dexamethasone Administered Over 48 Weeks</measure>
    <time_frame>48 weeks from baseline</time_frame>
    <description>Complete remission is defined as proteinuria &lt;0.3 g/d. Partial remission is defined as a 50% fall in proteinuria compared to baseline, proteinuria &lt;3.5 g/d, and a preserved estimated glomerular filtration rate (eGFR), specified as &gt;60% of baseline. Limited response is defined as a 50% fall in proteinuria compared to baseline. All other outcomes are described as non-response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urine Protein</measure>
    <time_frame>48 weeks from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CKD-EPI eGFR</measure>
    <time_frame>48 weeks from baseline</time_frame>
    <description>Estimate glomerular filtration rate (eGFR) using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula.</description>
  </secondary_outcome>
  <enrollment type="Actual">8</enrollment>
  <condition>Nephrosis</condition>
  <condition>Focal Lipoid Glomerulosclerosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral dexamethasone</intervention_name>
    <description>Stage I: Dexamethasone 25 mg/m2, 2 doses every 2 weeks over 48 weeks or dexamethasone 25 mg/m2, 4 doses every 4 weeks over 48 weeks.
Stage II: 1.) Dexamethasone 50 mg/m2, 2 daily doses every 12 weeks, followed by 25 mg/m2, 2 daily doses every 2 weeks over 36 weeks, or 2.) Dexamethasone 50 mg/m2, 4 daily doses every 4 weeks over 12 weeks, followed by 25 mg/m2, 4 daily doses every 4 weeks over 36 weeks.
over 36 weeks.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

               1. Adults and children greater than 2.0 years of age are eligible. We will exclude
                  children less than 2.0 years of age in light of the higher risk of steroid
                  therapy in this age group and the higher likelihood genetic or syndromic FSGS,
                  which is less likely to respond to steroids.

               2. Diagnosis:

                  A) Biopsy-proven MCD and its variants, including IgM nephropathy and MCD with
                  mesangial hypertrophy.

                  B) Biopsy-proven FSGS, including idiopathic FSGS and collapsing FSGS. We will
                  exclude patients with HIV-associated FSGS, as the risks of steroids are increased
                  in these patients. We will exclude hyperfiltration FSGS associated with morbid
                  obesity (BMI greater than 40 kg/m(2)), sickle cell anemia, reflux nephropathy,
                  chronic tubular injury, congenital renal anomalies, and reduced nephron mass; the
                  rationale is that these FSGS variants are considered refractory to steroids.

               3. Proteinuria: patients must have nephrotic range proteinuria. Baseline tests will
                  be obtained when patients have been off all immunosuppressive therapy for greater
                  than or equal to 1 month.

               4. Renal function: estimated GFR must be greater than or equal to 40 ml/min/1.73m(2)
                  at the time of study entry; In children weighing less than 40kg, GFR will be
                  estimated by the Schwartz formula and expressed as GFR/1.73m(2): GFR equal to
                  [0.7 (males) or 0.57 (females) X height (cm)]/ serum creatinine.

               5. Angiotensin antagonists: Patients must be receiving angiotensin antagonist
                  therapy, at any dose approved by the FDA. Nephrotic range proteinuria will be
                  defined as urine protein greater than or equal to 3.5 g/1.73m(2)/d (adults) and
                  greater than 50 mg/kg (children less than 40 kg) while receiving maximally
                  tolerated dose of angiotensin antagonist therapy for at least 4 weeks prior to
                  study entry.

               6. Prior immunosuppressive therapy:

                  For children with MCD, we require a minimum of 4 weeks and a maximum of 10 weeks
                  of daily steroid therapy at a dose of greater than or equal to 60 mg/m(2) with
                  proteinuria persisting in the nephrotic range (excluding steroid-sensitive,
                  steroid-dependent and frequently relapsing MDC).

                  For children with FSGS and adults with MCD and FSGS, we require no minimum and a
                  maximum of 8 weeks of daily or alternate day steroids at a dose of greater than
                  0.5 mg/kg with proteinuria persisting in the nephrotic range.

                  Patients with prior immunosuppressive therapy other than steroids are eligible.

               7. If hypertensive, adequate blood pressure control (target BP less than 125/75 mm
                  Hg at greater than 75% of measurements in adults).

               8. Women with reproductive potential who are sexually active must maintain an
                  effective birth control regimen (oral contraceptive, intrauterine device, or
                  barrier method plus spermicide) and must have a negative urine HCG test prior to
                  beginning therapy.

               9. Patients must either have a negative PPD test within 3 months of study entry
                  while off immunosuppressive therapy or, if they have a history of positive PPD,
                  they must have appropriate evaluation to exclude untreated tuberculosis (with the
                  advice of an Infectious Disease consultant).

        EXCLUSION CRITERIA:

          1. Patients with diabetes mellitus type 1 will be excluded, as these patients typically
             have brittle diabetic control that increases the risk of steroid treatment. Patients
             with diabetes mellitus type 2 will be included they manifest good glycemic control
             (glycosylated hemoglobin less than 7.5%), if they have lack proliferative retinopathy
             (the presence of proliferative retinopathy would place them at high risk for vision
             loss if steroids worsened glycemic control) and if they have had a renal biopsy within
             6 months of study entry that shows no evidence for diabetic nephropathy.

          2. Poorly controlled hypertension (greater than 25% of values greater than 125/75).

          3. Evidence of significant chronic or occult infection. Specifically, subjects must not
             have evidence of active hepatitis B or hepatitis C infection, or HIV-1 infection, or
             untreated mycobacterial infection. Minor infections, such as skin or nail fungal
             infections or other infections with the advice of an Infectious Disease consultant,
             will not be the basis for exclusion.

          4. Immunosuppressive medication other than glucocorticoids, whether for podocyte disease
             or another indication, must have been discontinued greater than 8 weeks prior to study
             entry. This does not apply to topical immunosuppressant medication.

          5. Pregnancy.

          6. Existence of any other condition that would complicate the implementation or
             interpretation of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2003-DK-0226.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Adhikari M, Bhimma R, Coovadia HM. Intensive pulse therapies for focal glomerulosclerosis in South African children. Pediatr Nephrol. 1997 Aug;11(4):423-8.</citation>
    <PMID>9260238</PMID>
  </reference>
  <reference>
    <citation>Yorgin PD, Krasher J, Al-Uzri AY. Pulse methylprednisolone treatment of idiopathic steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2001 Mar;16(3):245-50.</citation>
    <PMID>11322372</PMID>
  </reference>
  <reference>
    <citation>Houser MT, Jahn MF, Kobayashi A, Walburn J. Assessment of urinary protein excretion in the adolescent: effect of body position and exercise. J Pediatr. 1986 Sep;109(3):556-61.</citation>
    <PMID>3746552</PMID>
  </reference>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2003</study_first_submitted>
  <study_first_submitted_qc>July 28, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2003</study_first_posted>
  <results_first_submitted>September 20, 2011</results_first_submitted>
  <results_first_submitted_qc>September 20, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 28, 2011</results_first_posted>
  <last_update_submitted>September 20, 2011</last_update_submitted>
  <last_update_submitted_qc>September 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Steroids</keyword>
  <keyword>Osteoporosis</keyword>
  <keyword>Proteinuria</keyword>
  <keyword>Minimal Change Disease</keyword>
  <keyword>Focal Segmental Glomerulosclerosis</keyword>
  <keyword>FSGS</keyword>
  <keyword>MCD</keyword>
  <keyword>Kidney Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Nephrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>8 patients were enrolled in the study, 4 of them are randomized to 2 dose every 2 week arm and 4 of them are randomized to 4 dose every 4 week arm.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>2 Doses Every 2 Weeks Arm</title>
          <description>Patients in this arm receive 2 doses every 2 weeks</description>
        </group>
        <group group_id="P2">
          <title>4 Doses Every 4 Weeks Arm</title>
          <description>Patients in this arm receive 4 doses every 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>2 Doses Every 2 Weeks Arm</title>
          <description>Patients in this arm receive 2 doses every 2 weeks</description>
        </group>
        <group group_id="B2">
          <title>4 Doses Every 4 Weeks Arm</title>
          <description>Patients in this arm receive 4 doses every 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" spread="9"/>
                    <measurement group_id="B2" value="30" spread="5"/>
                    <measurement group_id="B3" value="35" spread="8" lower_limit="31" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urine Protein</title>
          <units>g/d</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.2" spread="7.0"/>
                    <measurement group_id="B2" value="10.0" spread="1.9"/>
                    <measurement group_id="B3" value="10.8" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CKD-EPI eGFR</title>
          <description>estimate glomerular filtration rate (GFR) using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula</description>
          <units>ml/min/1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.2" spread="13.4"/>
                    <measurement group_id="B2" value="76.3" spread="21.4"/>
                    <measurement group_id="B3" value="66.6" spread="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Remission Status of Patients After Intermittent Oral Dexamethasone Administered Over 48 Weeks</title>
        <description>Complete remission is defined as proteinuria &lt;0.3 g/d. Partial remission is defined as a 50% fall in proteinuria compared to baseline, proteinuria &lt;3.5 g/d, and a preserved estimated glomerular filtration rate (eGFR), specified as &gt;60% of baseline. Limited response is defined as a 50% fall in proteinuria compared to baseline. All other outcomes are described as non-response.</description>
        <time_frame>48 weeks from baseline</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>2 Doses Every 2 Weeks Arm</title>
            <description>Patients in this arm receive 2 doses every 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>4 Doses Every 4 Weeks Arm</title>
            <description>Patients in this arm receive 4 doses every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Remission Status of Patients After Intermittent Oral Dexamethasone Administered Over 48 Weeks</title>
          <description>Complete remission is defined as proteinuria &lt;0.3 g/d. Partial remission is defined as a 50% fall in proteinuria compared to baseline, proteinuria &lt;3.5 g/d, and a preserved estimated glomerular filtration rate (eGFR), specified as &gt;60% of baseline. Limited response is defined as a 50% fall in proteinuria compared to baseline. All other outcomes are described as non-response.</description>
          <population>ITT</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Limited response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial remission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete remission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9074</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urine Protein</title>
        <time_frame>48 weeks from baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>2 Doses Every 2 Weeks Arm</title>
            <description>Patients in this arm receive 2 doses every 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>4 Doses Every 4 Weeks Arm</title>
            <description>Patients in this arm receive 4 doses every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Protein</title>
          <units>g/d</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="0.7"/>
                    <measurement group_id="O2" value="6.2" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4566</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CKD-EPI eGFR</title>
        <description>Estimate glomerular filtration rate (eGFR) using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula.</description>
        <time_frame>48 weeks from baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>2 Doses Every 2 Weeks Arm</title>
            <description>Patients in this arm receive 2 doses every 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>4 Doses Every 4 Weeks Arm</title>
            <description>Patients in this arm receive 4 doses every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>CKD-EPI eGFR</title>
          <description>Estimate glomerular filtration rate (eGFR) using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula.</description>
          <units>ml/min/1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" spread="16"/>
                    <measurement group_id="O2" value="73" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3792</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>2 Doses Every 2 Weeks Arm</title>
          <description>Patients in this arm receive 2 doses every 2 weeks</description>
        </group>
        <group group_id="E2">
          <title>4 Doses Every 4 Weeks Arm</title>
          <description>Patients in this arm receive 4 doses every 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute appendicitis, increased intraocular pressure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Impaired glucose tolerance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>sleep disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Mood swings</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Change in appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Cushingoid appearance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle pains</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jeffrey B Kopp, MD</name_or_title>
      <organization>NIDDK, NIH</organization>
      <phone>3015943403</phone>
      <email>jbkopp@nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

